TICKERNERD
Menu
CVRXCVRXHealthcare · Medical Devices

CVRX Stock Forecast: CVRx, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.84
0.00% on the day

The 7 Wall Street analysts covering CVRx, Inc. hold a median 12-month price target of $4.5 — +58.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$75.7M
Ticker Nerd rank
34 / 100
Median analyst target
$4.50
Analysts covering
7
Total return, dividends reinvested
1W
−7.8%
1M
−42.9%
YTD
−60.0%
1Y
−62.5%
From 52W high
−73.7%
From 52W low
+19.8%
$2
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CVRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
79
Accruals
75
Volatility
62
Growth
59
Quality
50
Revisions
38
Value
25
Issuance
17
Momentum
14

Size (79): Smaller than most of the companies we track.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CVRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10Oct 25Jan 26Apr 26Jul 26CVRXHigh $6.00Median $4.50Low $3.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
3 Buy3 Hold1 Sell
Low $3.50Median $4.50High $6.00

The green dot is the last close — the median target sits +58.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Cantor FitzgeraldMaintainsOverweight$13 → $5.00
8 Aug 2026Lake StreetDowngradeHold—
7 Aug 2026Lake StreetDowngradeHold$14 → $3.50
14 Apr 2026Canaccord GenuityMaintainsBuy—
14 Apr 2026Canaccord GenuityMaintainsBuy$10
13 Feb 2026Canaccord GenuityMaintainsBuy—
6 Nov 2025Canaccord GenuityMaintainsBuy—
6 Nov 2025Cantor FitzgeraldMaintainsOverweight—
5 Aug 2025Cantor FitzgeraldReiteratesOverweight—
9 May 2025JP MorganDowngradeUnderweight—
9 May 2025Piper SandlerMaintainsOverweight—
8 Apr 2025Canaccord GenuityMaintainsBuy—
8 Apr 2025Lake StreetMaintainsBuy—
5 Feb 2025Canaccord GenuityMaintainsBuy—
5 Feb 2025Piper SandlerMaintainsOverweight—
17 Jan 2025Craig-HallumMaintainsBuy—
14 Jan 2025William BlairUpgradeOutperform—
9 Dec 2024Canaccord GenuityMaintainsBuy—
4 Nov 2024Craig-HallumMaintainsBuy—
30 Oct 2024Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CVRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

CVRx, Inc. (CVRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 83% of US stocks

Price / sales
1.2×

Cheaper than 65% of US stocks

Price / book
3.8×

Cheaper than 28% of US stocks

EV / EBITDA
−1.5×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
15.6%

Higher than 64% of US stocks

Earnings growth (YoY)
15.6%

Higher than 54% of US stocks

Gross margin
87.4%

Higher than 95% of US stocks

Operating margin
−82.9%

Higher than 14% of US stocks

Net margin
−84.9%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−133.4%

Higher than 10% of US stocks

Return on assets
−28.7%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CVRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CVRXCVRx, Inc.$75.7M
34
OMOutset Medical, Inc.$77.0M
29
MYOMyomo, Inc.$68.5M
45
NNOXNano-X Imaging Ltd.$67.6M
27
RPIDRapid Micro Biosystems, Inc.$83.7M
32
SERASera Prognostics, Inc.$83.8M
40
LUNGPulmonx Corp.$93.2M
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CVRx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CVRX news & analysis

CVRx, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Newsfile Corp · 18 Aug 2026negative

Law firm Block & Leviton is investigating CVRx, Inc. for potential securities law violations and is encouraging investors who have lost money in the company to contact the firm to learn about recovering their losses.

Why it matters — A securities fraud investigation signals potential concerns about CVRx's disclosures or conduct that CVRX watchers should be aware of.

CVRX ALERT: Securities Fraud Investigation by Block & Leviton Could Allow CVRx, Inc. Investors to Recover Losses

Newsfile Corp · 13 Aug 2026negative

Block & Leviton has launched a securities fraud investigation into CVRx, Inc. for potential violations of securities laws. The firm is reaching out to investors who have lost money in CVRX to inform them about possible recovery options.

Why it matters — This investigation signals potential legal and reputational risk for CVRx, which could weigh on investor confidence and the stock's near-term outlook.

CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches

MarketBeat · 13 Aug 2026positive

CVRx discussed its plans to expand adoption of its Barostim therapy for heart failure patients, focusing on sales-force execution, payer coverage progress, and a large post-market clinical trial. The company presented these efforts at Canaccord Genuity's 46th Annual Growth Conference.

Why it matters — A CVRX watcher would care because the company is detailing key drivers—commercial execution, reimbursement coverage, and clinical trial data—that could shape Barostim's broader market uptake.

Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Business Wire · 11 Aug 2026negative

The Law Offices of Frank R. Cruz announced an investigation into CVRx, Inc. for possible violations of federal securities laws, following the company's second quarter earnings report on August 6, 2026. Shareholders who lost money are being urged to contact the firm regarding potential claims.

Why it matters — CVRX investors should be aware that a securities fraud investigation has been launched, which could lead to legal action and potential financial liability for the company.

CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire · 11 Aug 2026negative

Law Offices of Howard G. Smith announced an investigation into CVRx, Inc. on behalf of investors concerning possible violations of federal securities laws. The firm is contacting investors who suffered losses in CVRX to discuss potentially pursuing claims to recover their losses.

Why it matters — CVRx shareholders may face heightened legal and regulatory scrutiny as a securities-fraud investigation is now underway concerning the company's conduct.

FAQ

Frequently asked questions about CVRX stock

What is the CVRX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering CVRx, Inc. have a median 12-month price target of $4.5, with estimates ranging from $3.5 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVRX stock a buy right now?

Of the 7 analysts covering CVRx, Inc., 3 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks CVRx, Inc. 34 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVRX?

As at 22 Aug 2026, CVRx, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

Will CVRX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +58.5% from the last close, and Ticker Nerd's factor model ranks CVRx, Inc. 34 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVRX stock forecast for 2030?

No analyst covering CVRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $6 over the next 12 months.

How has CVRX stock performed over the past year?

CVRx, Inc. returned -62.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CVRx, Inc. do?

CVRx, Inc. is a pioneering medical device company that focuses on developing innovative therapies to address a variety of cardiovascular conditions.

What is the latest news on CVRX?

The most recent item we track (Newsfile Corp, 18 Aug 2026): "CVRx, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm". Law firm Block & Leviton is investigating CVRx, Inc. for potential securities law violations and is encouraging investors who have lost money in the company to contact the firm to learn about recovering their losses.

Company

About CVRx, Inc.

CVRx, Inc. is a pioneering medical device company that focuses on developing innovative therapies to address a variety of cardiovascular conditions. The company's primary product is the Barostim Neo, a neuromodulation device designed to improve heart function by stimulating the body’s baroreceptors, which are essential for regulating blood pressure. CVRx aims to enhance the quality of life for patients with chronic heart failure and other cardiovascular diseases by offering this alternative treatment to traditional drug therapies. With a growing presence in the medical technology industry, CVRx, Inc. collaborates with healthcare providers and institutions worldwide to expand its reach and impact. Founded with a commitment to advancing patient care, the company plays a significant role in the cardiovascular segment, contributing to ongoing improvements in non-invasive treatment options. Headquartered in Minneapolis, Minnesota, CVRx continues to focus on research and development to further refine its technology and expand its product applications in the field of heart health management.

CEO Mr. Kevin Hykes · 223 employees · United States · https://www.barostim.com